Zeno Pharmaceuticals   Report issue

For profit Phase 1
Founded: San Diego CA United States (2014)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2018
NCT03446417
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Zeno Alpha Inc. | Zeno Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 1 Trials (4)

abemaciclib (verzenio) (1 trial)

palbociclib (ibrance) (1 trial)

zn-c5 (4 trials)

zn-e4 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 5
  • # of Trial APIs: 4